Skip to main content
EJNMMI Research
Figure 8 | EJNMMI Research

Figure 8

From: Synthesis and evaluation of 2-chloro N-[(S)-{(S)-1-[11 C]methylpiperidin-2-yl} (phenyl)methyl]3-trifluoromethyl-benzamide ([11 C]N-methyl-SSR504734) as a PET radioligand for glycine transporter 1

Figure 8

Time-activity curves of brain radioactivity after intravenous injection of [11 C]  N  -methyl-SSR504734 in rhesus monkey 2. (A) %SUV in brain regions at baseline condition. (B) %SUV in brain regions at pretreatment conditions (4.5 mg/kg of SSR5047). Black square, thalamus; white circle, pons; black triangle, cerebellum; white diamond, putamen; asterisk, frontal cortex; cross, white matter; black circle, caudate; white square, anterior cingulate cortex; white triangle, temporal cortex. (C) Time-activity curve (%SUV) of metabolite-corrected radioactivity in the plasma under baseline condition and pretreatment (4.5 mg/kg of SSR504734) condition.

Back to article page